{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:00:13Z","timestamp":1765526413917,"version":"3.48.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canrad.2025.104716","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:58:10Z","timestamp":1755741490000},"page":"104716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiotherapy of pancreatic cancers: 2025 update"],"prefix":"10.1016","volume":"29","author":[{"given":"Maxime","family":"Bertrand-Chevrier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Riou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Orthuon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Bessi\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Jaksic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Guimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12-13","key":"10.1016\/j.canrad.2025.104716_bib0255","first-page":"188","article-title":"Incidence des principaux cancers en France m\u00e9tropolitaine en 2023\u00a0et tendances depuis 1990","author":"Lap\u00f4tre-Ledoux","year":"2023","journal-title":"Bull Epidemiol Hebd"},{"year":"2024","series-title":"NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, V3","author":"Anon","key":"10.1016\/j.canrad.2025.104716_bib0260"},{"key":"10.1016\/j.canrad.2025.104716_bib0265","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1200\/JCO.2008.19.7921","article-title":"Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104716_bib0270","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/sj.bjc.6602513","article-title":"Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer","volume":"92","author":"Stocken","year":"2005","journal-title":"Br J Cancer"},{"issue":"9293","key":"10.1016\/j.canrad.2025.104716_bib0275","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2025.104716_bib0280","series-title":"Th\u00e9saurus national de canc\u00e9rologie digestive (TNCD)\u00a9","article-title":"Cancer du pancr\u00e9as","author":"Hammel","year":"2024"},{"issue":"11","key":"10.1016\/j.canrad.2025.104716_bib0285","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of folfirinox versus gemcitabine as adjuvant therapy for pancreatic cancer","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104716_bib0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/hpb.12061","article-title":"Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens","volume":"16","author":"Delpero","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.canrad.2025.104716_bib0295","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/MPA.0000000000000314","article-title":"Folfirinox-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies","volume":"44","author":"Petrelli","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.canrad.2025.104716_bib0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1245\/s10434-018-6931-6","article-title":"How does chemoradiotherapy following induction folfirinox improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An Ageo-French multicentric cohort","volume":"26","author":"Pietrasz","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104716_bib0305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"issue":"16","key":"10.1016\/j.canrad.2025.104716_bib0310","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104716_bib0315","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, folfirinox, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.canrad.2025.104716_bib0320","doi-asserted-by":"crossref","first-page":"S1323","DOI":"10.1016\/j.annonc.2023.10.084","article-title":"Neoadjuvant chemotherapy with folfirinox versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial","volume":"34","author":"Groot Koerkamp","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2025.104716_bib0325","doi-asserted-by":"crossref","first-page":"S1252","DOI":"10.1016\/j.annonc.2024.08.2304","article-title":"LBA62 Preoperative modified folfirinox (mfolfirinox) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS\/PRODIGE 44","volume":"35","author":"Lambert","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.canrad.2025.104716_bib0330","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mfolfirinox vs mfolfirinox plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2025.104716_bib0335","doi-asserted-by":"crossref","first-page":"S1136","DOI":"10.1016\/j.annonc.2022.07.1428","article-title":"PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)","volume":"33","author":"Ducreux","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.canrad.2025.104716_bib0340","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2025.104716_bib0345","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104716_bib0350","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.canrad.2025.104716_bib0355","doi-asserted-by":"crossref","first-page":"888462","DOI":"10.3389\/fonc.2022.888462","article-title":"Induction chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy for inoperable pancreas cancer","volume":"12","author":"Chuong","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104716_bib0360","doi-asserted-by":"crossref","first-page":"100506","DOI":"10.1016\/j.adro.2020.06.010","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104716_bib0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/cancers15010007","article-title":"Stereotactic MR-guided adaptive radiotherapy for pancreatic tumors: updated results of the Montpellier prospective registry study","volume":"15","author":"Bordeau","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2025.104716_bib0370","doi-asserted-by":"crossref","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multicenter, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104716_bib0375","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104716_bib0380","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2023.08.055","article-title":"Impact of short-course palliative radiation therapy on pancreatic cancer-related pain: prospective phase 2 nonrandomized PAINPANC trial","volume":"118","author":"Tello Valverde","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104716_bib0385","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13014-023-02367-5","article-title":"Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study","volume":"18","author":"Shibuki","year":"2023","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104716_bib0390","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijrobp.2022.02.038","article-title":"Single-fraction celiac plexus radiosurgery: a preliminary proof-of-concept phase 2 clinical trial","volume":"113","author":"Hammer","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104716_bib0395","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canrad.2023.04.007","article-title":"Radiation therapy of the primary tumour and\/or metastases of digestive metastatic cancers","volume":"28","author":"Huguet","year":"2024","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104716_bib0400","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.prro.2019.07.018","article-title":"Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT)","volume":"10","author":"Oar","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104716_bib0405","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ijrobp.2012.01.022","article-title":"Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer","volume":"83","author":"Goodman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.canrad.2025.104716_bib0410","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.ijrobp.2011.11.050","article-title":"Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American\u2013French consensus recommendations","volume":"83","author":"Huguet","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104716_bib0415","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijrobp.2009.10.043","article-title":"Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers","volume":"79","author":"Yovino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104716_bib0420","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijrobp.2003.11.003","article-title":"Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome","volume":"59","author":"Milano","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104716_bib0425","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijrobp.2003.11.019","article-title":"Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer","volume":"59","author":"Ben-Josef","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104716_bib0430","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ijrobp.2008.07.010","article-title":"Evaluation of four-dimensional computed tomography-based intensity-modulated and respiratory-gated radiotherapy techniques for pancreatic carcinoma","volume":"72","author":"Van der Geld","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104716_bib0435","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1748-717X-6-147","article-title":"Bilateral kidney preservation by volumetric-modulated arc therapy (RapidArc) compared to conventional radiation therapy (3D-CRT) in pancreatic and bile duct malignancies","volume":"6","author":"Vieillot","year":"2011","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104716_bib0440","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0958-3947(02)00094-8","article-title":"Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity","volume":"27","author":"Landry","year":"2002","journal-title":"Med Dosim"},{"key":"10.1016\/j.canrad.2025.104716_bib0445","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","article-title":"A phase I\/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer","volume":"84","author":"Ben-Josef","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.canrad.2025.104716_bib0450","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.meddos.2014.04.001","article-title":"Volumetric-modulated arc radiotherapy for pancreatic malignancies: dosimetric comparison with sliding-window intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy","volume":"39","author":"Nabavizadeh","year":"2014","journal-title":"Med Dosim"},{"key":"10.1016\/j.canrad.2025.104716_bib0455","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.meddos.2011.10.001","article-title":"Dosimetric comparison of volumetric modulated arc therapy and intensity-modulated radiation therapy for pancreatic malignancies","volume":"37","author":"Ali","year":"2012","journal-title":"Med Dosim"},{"key":"10.1016\/j.canrad.2025.104716_bib0460","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00066-010-2094-5","article-title":"Volumetric modulated arc therapy for advanced pancreatic cancer","volume":"186","author":"Eppinga","year":"2010","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2025.104716_bib0465","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","article-title":"ESTRO ACROP guidelines for target volume definition in pancreatic cancer","volume":"154","author":"Brunner","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104716_bib0470","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.canrad.2025.104716_bib0475","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104716_bib0480","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104716_bib0485","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.canrad.2025.104716_bib0490","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose\u2013volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.canrad.2025.104716_bib0495","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijrobp.2014.10.058","article-title":"Modeling pancreatic tumor motion using 4-dimensional computed tomography and surrogate markers","volume":"91","author":"Huguet","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.canrad.2025.104716_bib0500","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:55:31Z","timestamp":1765526131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1278321825001325"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104716","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy of pancreatic cancers: 2025 update","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104716"}}